Dexamethasone Treatment Induces the Reprogramming of Pancreatic Acinar Cells to Hepatocytes and Ductal Cells by Al-Adsani, Amani et al.
Dexamethasone Treatment Induces the Reprogramming
of Pancreatic Acinar Cells to Hepatocytes and Ductal
Cells
Amani Al-Adsani
1., Zoe ¨ D. Burke
1., Daniel Eberhard
1, Katherine L. Lawrence
1, Chia-Ning Shen
2, Anil K.
Rustgi
3, Hiroshi Sakaue
4, J. Mark Farrant
5, David Tosh
1*
1Department of Biology and Biochemistry, Centre for Regenerative Medicine, University of Bath, Bath, United Kingdom, 2Stem Cell Program, Genomics Research Center,
Academia Sinica, Taipei, Taiwan, Republic of China, 3Department of Medicine and Genetics, Abramson Cancer Center, University of Pennsylvania, Philadelphia,
Pennsylvania, United States of America, 4Department of Nutrition and Metabolism, Institute of Health Biosciences, The University of Tokushima Graduate School,
Tokushima, Japan, 5Department of Gastroenterology, Royal United Hospital, Bath, United Kingdom
Abstract
Background: The pancreatic exocrine cell line AR42J-B13 can be reprogrammed to hepatocytes following treatment with
dexamethasone. The question arises whether dexamethasone also has the capacity to induce ductal cells as well as
hepatocytes.
Methodology/Principal Findings: AR42J-B13 cells were treated with and without dexamethasone and analyzed for the
expression of pancreatic exocrine, hepatocyte and ductal markers. Addition of dexamethasone inhibited pancreatic amylase
expression, induced expression of the hepatocyte marker transferrin as well as markers typical of ductal cells: cytokeratin 7
and 19 and the lectin peanut agglutinin. However, the number of ductal cells was low compared to hepatocytes. The
proportion of ductal cells was enhanced by culture with dexamethasone and epidermal growth factor (EGF). We established
several features of the mechanism underlying the transdifferentiation of pancreatic exocrine cells to ductal cells. Using a
CK19 promoter reporter, we show that a proportion of the ductal cells arise from differentiated pancreatic exocrine-like
cells. We also examined whether C/EBPb (a transcription factor important in the conversion of pancreatic cells to
hepatocytes) could alter the conversion from acinar cells to a ductal phenotype. Overexpression of an activated form of C/
EBPb in dexamethasone/EGF-treated cells provoked the expression of hepatocyte markers and inhibited the expression of
ductal markers. Conversely, ectopic expression of a dominant-negative form of C/EBPb, liver inhibitory protein, inhibited
hepatocyte formation in dexamethasone-treated cultures and enhanced the ductal phenotype.
Conclusions/Significance: These results indicate that hepatocytes and ductal cells may be induced from pancreatic
exocrine AR42J-B13 cells following treatment with dexamethasone. The conversion from pancreatic to hepatocyte or ductal
cells is dependent upon the expression of C/EBPb.
Citation: Al-Adsani A, Burke ZD, Eberhard D, Lawrence KL, Shen C-N, et al. (2010) Dexamethasone Treatment Induces the Reprogramming of Pancreatic Acinar
Cells to Hepatocytes and Ductal Cells. PLoS ONE 5(10): e13650. doi:10.1371/journal.pone.0013650
Editor: Irene Oi Lin Ng, The University of Hong Kong, Hong Kong
Received March 24, 2010; Accepted September 19, 2010; Published October 27, 2010
Copyright:  2010 Al-Adsani et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Government of Kuwait and the Wellcome Trust (073381). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: d.tosh@bath.ac.uk
. These authors contributed equally to this work.
Introduction
Transdifferentiation belongs to the wider class of cell type
conversions known as reprogramming [1]. One example of
reprogramming is the conversion of pancreatic cells to hepato-
cytes. The appearance of hepatic foci in adult pancreas has been
observed in rodent models and cancer patients [2,3,4,5].
We previously developed an in vitro model for studying the
reprogramming of pancreatic cells to hepatocytes based on the
addition of the synthetic glucocorticoid dexamethasone (Dex) to
AR42J-B13 (B13) cells [6,7]. B13 cells are derived from a rat
pancreatic tumour [8] and display both exocrine and neuroendo-
crine properties [9]. When cultured with Dex for 14 days,
pancreatic AR42J-B13 cells begin to express markers typical of
hepatocytes [6,7]. We have recently shown that the phosphoino-
side 3-kinase pathway is important in the transdifferentiation of
pancreatic acinar cells to hepatocytes and that the hepatocytes
arise from acinar cells via an intermediate expressing the ATP-
binding cassette sub-family G member 2 (ABCG2) [10]. In
addition to hepatocytes, AR42J cells may be induced to also form
insulin-producing b-cells following treatment with hepatocyte
growth factor (HGF) and activin [11] suggesting the cells may
exhibit a progenitor phenotype. The question arises whether other
types of cells (apart from hepatocytes), are induced following Dex
treatment of AR42J-B13 cells. The reason for specifically
examining the ductal phenotype is two-fold. First, during liver
development, bipotential hepatoblasts can differentiate towards
either hepatocyte or biliary lineages [12]. Second, acinar-ductal
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13650transdifferentiation is clinically significant because it may predis-
pose to the development of neoplasia [13]. Transdifferentiation of
primary acinar cells to ductal cells occurs when the cells are placed
in primary culture [14,15] Acinar-to-ductal transdifferentiation
may occur in experimental pancreatitis and in the progression to
pancreatic neoplasia [16,17,18,19].
In models of adult pancreatic regeneration, exocrine acini are
found to transdifferentiate to duct-like complexes in a process
called acinar-ductal metaplasia (reviewed in [20]). This form of
metaplasia is also observed in a model of pancreatic ductal ligation
[21]. In the present study we have investigated the potential of
AR42J-B13 cells to differentiate towards other cell types (apart
from hepatocytes) following Dex treatment. We show that (i)
ductal cells are formed in Dex-treated B13 cells, (ii) the number of
ductal cells can be increased by treatment with Dex and epidermal
growth factor (Dex/EGF) in combination (iii) ductal cells can arise
from exocrine (amylase-positive) cells and (iv) overexpression of
CCAAT enhancer binding protein b (C/EBPb), a transcription
factor previously shown to mediate hepatocyte transdifferentiation
of pancreatic cells, inhibits conversion to a ductal phenotype.
Results
Expression of ductal markers in adult rat liver and
pancreas
In order to test the utility of our antibodies in adult rat liver and
pancreas tissue (rat tissue was used because B13 cells are also of rat
origin [8]), we determined initially the expression pattern of the
markers CK7, CK19, CK20 and OV6 (Figure 1). As expected, the
antibodies to the ductal markers CK7, CK19 and CK20 stained
the intrahepatic bile ducts (but not hepatocytes) in the liver,
whereas the oval cell marker OV6 was only expressed in the
Figure 1. Expression of ductal markers in adult rat liver and pancreas tissue. Immunohistochemistry for cytokeratin 7 (CK7), cytokeratin 19
(CK19), cytokeratin 20 (CK20), OV6 and Peanut Agglutinin (PNA) in adult rat liver and pancreas sections. A control (no primary antibody) is also shown.
All scale bars, 100 mm.
doi:10.1371/journal.pone.0013650.g001
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pancreas, ducts (but not acinar or endocrine cells) were positive for
CK7, CK19 and CK20 and OV6 (Figure 1). Ducts in the liver and
the pancreas were also positive for the epitope recognised by the
lectin Peanut Agglutinin (PNA). Thus PNA can be used as a ductal
marker along with cytokeratins 7 and 19 (Figure 1). We did not
observe any non-specific staining in the absence of primary
antibody (Figure 1).
Dex treatment of AR42J-B13 cells induces both
hepatocyte and ductal phenotypes
We cultured B13 cells with or without Dex a period of 10 days
and examined the expression of pancreatic exocrine, hepatocyte
and ductal markers (Figure 2). The majority of control AR42J-B13
cells co-expressed the exocrine marker amylase and CK20, which
labels both progenitor-like and ductal cells [22]. The cells were
also weakly positive for OV6 and PNA. Control B13 cells did not
express the hepatocyte marker transferrin (TFN) (Figure 2) or the
ductal-specific markers CK7 and Connexin 43 (Cx43) (Figure 2).
During Dex treatment, amylase expression is lost in AR42J-B13
cells which also begin to express the hepatocyte marker TFN
(Figure 3A), as reported previously [6]. After treatment with Dex
for 3 days a small number of cells expressing the ductal markers
CK7 and CK19 were detected and expression of CK20, OV6 and
the binding sites for PNA were enhanced (data not shown). Some
cells still expressed CK7, CK20, OV6 and PNA following
treatment with Dex for 10 days (Figure 2, Figure 3B). However,
only around 2% of the cells were positive for CK7 compared with
16.5% for transferrin in Dex-treated cultures (Figure 3B).
EGF enhances the number of ductal-like cells in Dex-
treated cultures
As the incidence of ductal cells (based on immunostaining for
CK7) is uncommon in Dex-treated cultures, we tried to enhance
the number of ductal cells by addition of extracellular factors. EGF
is one such candidate factor since EGF receptor stimulation in
pancreatic tissue induces an acinar to ductal metaplasia [23,24].
We tried different combinations of Dex and EGF treatment on
B13 cells. When treated with 1 mM Dex for 4 days followed by
20 ng/ml EGF treatment for 6 days (the combined treatment will
be referred to as Dex/EGF from now on), the percentage of cells
staining positive for CK7, CK20 and the lectin PNA, increased
compared to cells treated with EGF or Dex for 10 days (Figure 2,
Figure 3B). In addition the ductal markers Cx43 and GSTp were
detected only in Dex/EGF-treated cells by immunostaining (Cx43)
and RT-PCR (Cx43 and GSTp) (Figure 2 and Figure 4A
respectively). Cx43 expression was localised in a punctate pattern
on membranes of opposing cells (Figure 2). When B13 cells were
treated for 10 days with EGF alone, amylase expression was lost in
a proportion of cells (Figure 3A; 53.6% in EGF treated compared
to 86.6% in control cells), but only a few cells weakly expressed the
ductal markers CK7 or CK20. However, no transferrin positive
cells were observed, suggesting the absence of cells with a
hepatocyte phenotype (Figure 2 and Figure 3A).
In order to determine the number of cells expressing ductal
markers, we counted the total number of cells in randomly chosen
fields and calculated the percentage of those cells expressing the
markers CK7, CK20, PNA and OV6 (Figure 3B). In Dex/EGF
samples there was a significant increase in the percentage of cells
expressing CK20 (p=0.0043), PNA (p=0.0098) and OV-6
(p,0.0001) compared to treatment with Dex or EGF alone. The
percentage of cells expressing CK7 was also higher in Dex/EGF
treated samples compared to controls (Figure 3B).
Since the combined treatment of Dex and EGF considerably
enhanced the binding sites for PNA, we focused on quantifying the
percentage of cells expressing high levels of PNA in Dex/EGF-
treated cultures using a FACScanto cell sorter. PNA was used to
sort the cells as this cell surface marker allows labelling of the cells
without compromising cell integrity. Cells were labelled with a
FITC-conjugated PNA antibody and sorted according to the
FITC intensity. Approximately 24% of cells treated with Dex/
EGF were intensely FITC positive (Figure 3C) and likely represent
the ductal cells exhibiting strong PNA by immunostaining. In
order to determine the expression of ductal markers in a more
homogeneous population of cells, we used Magnetic activated cell
sorting (MACS) to enrich for a population of ductal cells. Cells
were labelled with biotinylated-PNA and sorted using the
MiniMACS system. Both positive and negative cell fractions were
collected and the cells returned to culture in the presence of EGF.
Sorted cells were immunostained for CK7 and Sox9. PNA
directed enrichment of ductal cells was confirmed in the positive
cell fraction in which 25% of cells stained positive for the ductal
marker CK7 (p=0.0079) and 82% for the ductal specific
transcription factor Sox9 (p=0.0028) (Figure 3C).
To confirm the increase in ductal cells was due to the specific
affect of EGF treatment, we added the EGF receptor inhibitor
AG1478 to pancreatic cells from day 1 of EGF treatment. We
were able to inhibit ductal cell formation as indicated by the loss of
CK7 expression in inhibitor-treated samples (Figure 4C).
We have also tested the ability of primary acinar cells and
additional pancreatic cell lines such as Capan1 and Panc-1 to
differentiate towards hepatocyte and ductal cell phenotypes. Our
preliminary data suggests that neither Capan1 nor Panc1 cells can
be induced with Dex to generate hepatocytes (unpublished
observations). In contrast, primary mouse acinar cells transdiffer-
entiate to generate transferrin and C/EBPb-positive hepatocytes
[10]. However, due to contamination of the primary cultures with
ductal cells we were unable to determine the ability of the acinar
cells to transdifferentiate to ductal-like cells.
To determine the affect of Dex/EGF treatment on the hepatic
phenotype, we analysed the protein levels of the liver markers
alpha-fetoprotein, albumin, transferrin and the transcription factor
C/EBPb by Western blotting (Figure 4B). Albumin, AFP and TFN
were induced in both Dex and Dex/EGF treated cells (Figure 4B),
however, liver protein levels were much higher in Dex-treated
compared to those treated with Dex/EGF. Furthermore, the liver
enriched transcription factor C/EBPb was detected only in the
Dex treated cells (data shown for 10 day treatment only).
Ultrastructure of Ductal-like Cells
We examined the ultrastructural characteristics of the Dex and
EGF treated cells by electron microscopy to identify the subcellular
morphology of ductal type cells. The presence of prominent
microvillialongtheplasmamembraneinisolatedandculturedadult
ductshasbeendescribed[25] and suchstructuresareessentialtothe
normal function of these cells in vivo [26]. Control and Dex-treated
cells possessed only small sparse microvilli while we observed well-
formed microvilli projecting from the surface of Dex/EGF treated
cells (Figure 5A). Given that our cultures are heterogeneous
(containing undifferentiated B13 cells, reprogrammed hepatocytes
as well as ductal cells) and the sample size for EM analysis is very
small, it was not possible to quantify cell numbers to directly
compare with immunostaining data.
Stability of the Ductal Phenotype
We were interested to know whether the ductal phenotype was
dependent upon the continued presence of Dex and EGF or
Ductal Cell Reprogramming
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revert to the parent cell of origin. To address this question, we
examined the stability of the ductal cells after withdrawal of Dex
and EGF. B13 cells were treated initially for 4 days with Dex and 6
days with EGF, the EGF was then withdrawn and cells fixed at 3,
5 and 7 days later and stained for amylase, CK7 and CK20. Cells
positive for CK7 and CK20 were still present 7 days after
discontinuing EGF treatment as judged by immunofluoresence
(Figure 5B) and the amylase-expressing cells did not increase
significantly. This suggests that, once induced, the ductal
phenotype is stable (at least for the time points examined) in the
absence of Dex and EGF.
Exocrine cells are precursors of the ductal cells
Since Dex treatment also induced the hepatocyte phenotype,
ductal cells might arise from these cells or directly from exocrine
cells. To distinguish some of these possibilities and determine the
origin of these cells, we co-stained for exocrine and hepatocyte or
ductal markers. A transitional expression of both markers would
be expected if the ductal cells arise from the exocrine cells by direct
conversion. Due to the requirement for different fixatives we were
unable to stain cells for amylase (paraformaldehyde fixation) and
CK7 (acetone:methanol fixation). Therefore, we used an alterna-
tive approach to determine the ductal cell lineage. Ductal cells
were traced using an adenoviral reporter construct in which the
CK19 promoter was used to drive GFP expression. Since CK7
and CK19 occur as a heterotypic pair and both exhibit specificity
for ductal cells types (Figure1), we used the CK19 promoter to
drive the GFP reporter. The fidelity of expression of the CK19
promoter construct was tested by infection of control B13 cells
(negative control) and HepG2 cells. HepG2 cells were used as a
positive control since the hepatoma expresses CK19 [27]. HepG2
Figure 3. EGF enhances the ductal phenotype at the expense of the hepatic phenotype. Bar charts showing the percentage of cells
expressing (A) Amylase and Transferrin (B) CK7, CK20, PNA and OV-6 in control, EGF, Dex/EGF and Dex treated cells. (C) Scatter plot from the
FACSCanto showing the intensity of PNA staining in Dex/EGF treated cells and bar charts showing percentage of cells positive for CK7 and Sox9
(positive fraction) following MACS isolation. Scale bars, top and middle row, 20 mm; lower row, 50 mm.
doi:10.1371/journal.pone.0013650.g003
Figure 2. Differentiation of B13 cells to ductal and hepatic phenotypes. Immunostaining for Amylase (red)/CK20 (green), TFN (red)/CK20
(green), PNA, OV6, CK7, Cx43 (green) in untreated (control, CTL), DEX, Dex/EGF and EGF treated B13 cells. Scale bars, first and second row, 20 mm; all
others 40 mm.
doi:10.1371/journal.pone.0013650.g002
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these cells (Figure 6A) while the control B13 cells (which do not
normally express CK19) were negative for GFP (Figure 6A), thus
confirming there was no ‘leakiness’ of promoter expression. GFP
expression was detected in Dex/EGF treated cells indicating that
cells with a ductal phenotype are present and capable of activating
the CK19 promoter. The adenoviral vector was introduced into
B13 cells after 4 days of Dex and 2 days of EGF treatment
presumably when the cells were just switching from one phenotype
to another. B13 cells infected with AdCK19-nucGFP were
cultured for up to 4 days, then fixed and stained for the exocrine
marker amylase. We found that a subpopulation of GFP-
expressing cells still expressed amylase (Figure 6B). While no
GFP positive cells were found to express the hepatic marker TFN.
Although we cannot exclude the possibility that EGF is causing
proliferation of existing ductal cells within the culture, this data
suggests that at least some of the ductal cells may arise directly
from exocrine cells but not from hepatocytes. We also observed
GFP positive/amylase negative cells. These cells may have lost
their amylase expression at the time of analysis.
Role of CCAAT enhancer binding protein b in formation
of ductal cells
The CCAAT enhancer binding proteins (C/EBP) are basic
region/leucine zipper (bZIP) transcription factors expressed
during differentiation of adipose tissue and liver [28]. One
member of the C/EBP family, C/EBPb, is transcribed into one
mRNA which can be translated into three distinct isoforms
designated C/EBPb, Liver Activating Protein (LAP) and Liver
Inhibitor Protein (LIP) [29]. The 21 kDa LIP lacks the
transactivation domain of LAP and acts as a dominant-negative
form of C/EBPb by heterodimerizing with the full length C/
EBPb. We showed previously that C/EBPb is required for the
transdifferentiation of pancreatic B13 cells to hepatocytes
[6,7,30]. To determine whether C/EBPb is required for the
formation of ductal cells, we stained control, Dex, EGF and Dex/
EGF-treated cells for C/EBPb. C/EBPb was absent in control
(Figure. 7A) and EGF-treated cells (data not shown), but present
at very low levels in Dex/EGF cultures. Robust staining for C/
EBPb was detected in Dex treated cells staining positive for the
liver marker TFN but not in cells staining for PNA (Figure 7A).
Western blotting for C/EBPb confirmed that C/EBPb was
expressed in Dex treated cells at a higher level than in control
cells and cells treated with Dex/EGF (Figure 4B). To test whether
overexpression or inhibition of C/EBPb can influence the
direction of reprogramming (i.e. hepatocyte vs ductal), we
infected control, Dex and Dex/EGF-treated cells with the
adenoviral vectors containing either LAP or LIP (Ad-CMV-
LAP or Ad-CMV-LIP) and determined the expression of the
hepatocyte marker TFN or the ductal marker PNA. The C/
EBPb antibody used in these experiments recognises the carboxyl
terminus and therefore detects all three forms of C/EBPb.I n
agreement with previous observations [6], LAP induced the liver
marker TFN in control B13 cells and enhanced the expression of
the hepatocyte marker in Dex-treated cultures. Dex/EGF treated
cells (which do not normally express TFN in many cells) were
induced to do so following infection with Ad-CMV-LAP
(Figure 7A). Cells expressing the transgene, did not express the
ductal marker PNA suggesting that overexpression of C/EBPb
can inhibit the formation of ductal cells and induce a hepatocyte
phenotype. Conversely, overexpression of LIP in Dex-treated
cultures inhibits hepatocyte formation and induces the ductal
phenotype (Figure 7B). This suggests that LIP might inhibit
endogenous C/EBPb activity and enhance the ductal phenotype.
Figure 4. Expression of ductal markers and inhibition of the ductal phenotype. (A) RT-PCR for Cx43 and GSTp (B) Western blotting analysis
for Albumin, TFN, AFP and the liver enriched transcription factor C/EBPb in control, EGF, Dex/EGF and Dex treated cells. b-actin and a-tubulin are also
shown as loading controls. (C) Immunostaining for CK7 in control and Dex/EGF treated cells in the presence and absence and absence of the EGF
receptor inhibitor AG1478. The inhibitor was added at a final concentration of 25 mM.
doi:10.1371/journal.pone.0013650.g004
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Acinar-ductal transdifferentiation is clinically significant as it is
present in pancreatitis. The switch from acinar to ductal cell can be
induced in vivo by pancreatic ductal ligation [21], overexpression of
Pdx1 [31], or in vitro by the addition of external factors (DMSO) [32]
or EGF [19,24]. In the present study, we demonstrate that cells
resembling a ductal phenotype are also induced following treatment
of pancreatic B13 cells with Dex. The efficiency of conversion to a
ductal phenotype is very low but can be enhanced by a combined
treatment of Dex followed by EGF. Dex treatment has been shown
previously to induce the conversion of pancreatic cells towards a
hepatocyte phenotype [6,7,30,33]. Remarkably, the conversion to
ductal cells is stable as ductal cells maintained their phenotype for at
least for 7 days after withdrawal of EGF. These observations suggest
a bistable switch operates in which pancreatic B13 cells can generate
either hepatocytes or ductal cells following Dex treatment. Due to
the acinar nature (amylase-expression) of the B13 cells it is possible
that the cells can undergo acinar-ductal metaplasia similar to that
described in a number of other systems [20,32,34]. The evidence for
agenuineacinar-ductalconversionintheB13 cellmodelisthreefold.
First,thetypicalductcytokeratinCK7isinducedaftertreatmentand
are not present in control cells. Moreover, other duct and progenitor
markers suchasCK20, OV-6 and PNA are increased inDex treated
Figure 5. Electron microscopy and stability of the ductal phenotype. (A) Electron micrographs of control, Dex and Dex/EGF treated B13 cells.
(B) Immunostaining for amylase, CK20 and CK7 following withdrawal of Dex and EGF in treated B13 cells. Control B13 cells are also shown (B). Scale
bars for electron micrographs are (from left to right); 2, 2, 1 and 0.5 mm. Scale bars in second row, 20 mm and 40 mm for all others.
doi:10.1371/journal.pone.0013650.g005
Ductal Cell Reprogramming
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13650compared to untreated cultures. Second, morphological and
ultrastructural features reminiscent of ductal cells (such as well-
formed microvilli) are present. Third, we were able to identify a
population of cells co-expressing amylase and CK19 (as shown by a
GFP reporter construct) which indicates an intermediate population
of amylase expressing cells may generate at least some of the ductal
cells. At the same time there were no cells co-staining for hepatocyte
markers andCK19. Therefore, we proposethat ductal cells can arise
from amylase-positive acinar cells following treatment with Dex and
that ductal cells form a separate population of cells independent of
the reprogrammed hepatocytes (Figure 8).
The question arises: what is the mechanism of the increase in
ductal cells following EGF treatment? At least three possibilities
exist. The first is that EGF acts directly on ductal cells formed
during reprogramming of acinar cells to promote proliferation. The
second is that EGF promotes cell death of non-ductal cells
increasing the overall proportion ofductal cells.Thethirdpossibility
is that EGF directly promotes the reprogramming of pancreatic
acinar cells to ductal cells. Using the existing model it is not possible
to distinguish which of these mechanisms are in operation. Further
studies are required to elucidate the cellular basis underpinning the
role of EGF in enhancing ductal cell numbers.
Previous studies have revealed the role of transcription factors
inducing acinar-ductal conversion in vivo and in vitro. For example,
ectopic expression of Pdx1 in acinar cells has been shown to
reprogram cells to a ductal phenotype through activation of the
Stat3 pathway in the mouse [31]. In our model, we were
particularly interested in the role of the liver-enriched transcrip-
tion factor C/EBPb. Previous work by our lab [6] suggested that
C/EBPb is required for transdifferentiation of pancreatic B13 cells
to hepatocytes. As expected, C/EBPb levels were much higher in
cells treated with Dex compared to Dex/EGF treated cells. This
difference is probably due to the fact that fewer hepatocyte-like
cells are induced following treatment with Dex/EGF.
We found that the C/EBPb splice variants LAP and LIP (liver-
activating and inhibitory proteins) play important roles in
switching B13 cells towards a ductal or hepatic cell type.
Adenoviral-mediated overexpression of LAP reprogrammed B13
cells towards a hepatocyte phenotype. PNA stained cells were
devoid of LAP suggesting that LAP suppresses the ductal
phenotype and promotes the hepatic phenotype. In contrast, cells
overexpressing LIP were PNA positive suggesting that LIP
promotes ductal rather than hepatic differentiation under Dex-
treated conditions. LIP, which lacks the transactivation domain of
LAP, may antagonize the effect of low levels of endogenous C/
EBPb present in B13 cells and promote their ductal differentiation.
We propose that in addition to hepatocytes, ductal-like cells are
formed following Dex treatment of pancreatic B13 cells. Ductal-
Figure 6. Lineage trace of ductal phenotype. (A) Infection of HepG2, control B13 and Dex/EGF treated B13 cells with Ad-CK19-nucGFP and (B)
immunostaining for amylase and TFN in Dex/EGF treated B13 cells infected with Ad-CK19-nucGFP.
doi:10.1371/journal.pone.0013650.g006
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demonstrated that Dex/EGF treatment activated the CK19
promoter in amylase expressing cells suggesting an ancestor-
descendent relationship between amylase-positive cells and ductal
cells. Furthermore, the hepatic master switch gene C/EBPb
appears to be reduced during the induction of ductal cells and
when overexpressed inhibits the ductal phenotype. This data
suggests that C/EBPb is the master gene for hepatocytes.
Materials and Methods
Ethics Statement: Animals
All animal experiments were performed under the UK Home
Office guidelines. The handling of animals involved Schedule 1
killing by authorised personnel and thus did not require protocol
review.
Cell culture conditions
AR42J-B13 cells were a generous gift from Professor Itaru
Kojima (Institute for Molecular and Cellular Regulation Gunma
University, Gunma, Japan. AR42J-B13 cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) as
described previously [6]. For immunostaining, cells were seeded
at 10–15% confluency on sterile glass coverslips (22 mm622 mm).
Cells were cultured at 37uC in a humidified incubator with 5%
CO2 and 95% air. To induce transdifferentiation, cells were
treated with 1 mM Dex (Sigma, Poole, UK) for 10 or 14 days,
1 mM Dex for 4 days then with 20 ng/ml of EGF (R&D systems,
Abingdon, UK) for 6 days, or 20 ng/ml EGF alone for 10 days.
To inhibit the EGF signalling pathway the EGF receptor inhibitor
AG1478 (Calbiochem) (final concentration of 25 mM) was added
to cultures at the same time as EGF and cultured for 6 days.
Immunofluorescent staining of cell cultures
B13 cells were immunostained as described previously [35,36]
with the following modifications. Cells were fixed either with 4%
paraformaldehyde (PFA) (Fisher scientific, Leicestershire, UK) in
PBS, pH 7.4 for 20–30 mins at room temperature or ice cold
acetone:methanol (Ac:Me, 1:1) for 5 mins depending on the
antibody under investigation. In some cases, PFA-fixed cells were
post-fixed with Ac:Me for 5 minutes. Prior to immunostaining, PFA
fixed cells were permeabilised in 0.1% (v/v) Triton X-100 (Sigma,
Poole, UK) for 30 min. Permeabilisation was not necessary for cells
fixed with Ac:Me. Antigen retrieval was then performed on Ac:Me
fixed cells using either 1x (v/v) EDTA or citrate buffer (Lab vision,
Newmarket, UK) at 37uC. Non-specific binding sites were blocked
for 30 min in 2% blocking buffer (Roche) or 10% normal goat
serum (NGS). Primary antibodies and dilutions used were: rabbit-
anti-amylase (1:100, Sigma, Poole, UK), mouse-anti-cytokeratin
(CK) 7 (used neat, a generous gift from Dr. Birgit Lane or Abcam
1:40, Cambridge, UK), mouse-anti-CK20 (1:50, DAKO, High
Wycombe, UK), mouse and rabbit-anti-C/EBPb (1:100, Santa
Cruz Biotechnology, CA, USA), mouse-anti-OV6 (1:3000, a
generous gift from Dr. Stewart Sell, Albany Medical College) and
rabbit-anti-transferrin(TFN)(1:200,DAKO,HighWycombe,UK),
mouse-anti-Connexin 43 (Cx43)(1:25, Sigma, UK). The fluorescein
conjugated lectin, peanut agglutinin (PNA) (1:100, Vector Labora-
tories, Peterborough, UK), was also used to stain cells. Secondary
antibodies used were rabbit-anti-sheep-Texas Red, horse-anti-
mouse-fluorescein isothiocyanate (FITC), goat-anti-rabbit-FITC,
horse-anti-mouse-Texas Red and goat-anti-rabbit-Texas Red (all
1:200, Vector Laboratories, Peterborough, UK). Images were
collected on a Zeiss LSM 510 confocal microscope and collated into
Figures in Adobe Photoshop 7.0. Cells were counted manually as
percentages of positive cells per field. Five fields were counted per
sample and each sample was performed in triplicate. Statistical
differences between treatments was determined using the un-paired
Student t-test in GraphPad Prism software version 4.03 (GraphPad
Software, San Diego, CA, USA).
Immunohistochemistry of adult rat tissue
Following cervical dislocation, adult rat pancreatic and liver tissue
were removed, washed in PBS and fixed with either Ac:Me for
1 hour or 4% PFA over night. The tissue samples were then washed
again three times in PBS and left in 70% ethanol for 1 to 3 hours
before processing. Fixed tissue was paraffin embedded, sectioned,
dewaxed and rehydrated. PFA fixed pancreas and liver sections were
permeabilised with 0.5% (v/v) Triton X-100 for 30 minutes. Antigen
retrieval was then performed using either 1x (v/v) EDTA or citrate
buffer for 30 minutes at 90uC. Afterwards, the slides were allowed to
cool for a further 30 minutes at room temperature. Sections were
incubated with peroxidase block solution (DAKO Envision perox-
idase system, DAKO) to prevent endogenous peroxidase activity.
Non-specific binding was blocked by either adding 2% blocking
buffer or 10% (v/v) NGS and 0.5% (v/v) bovine serum albumin
(BSA)inPBS.Primaryantibodiesweredilutedasfollows:mouse-anti-
CK7 (1:50), mouse-anti-CK20 (1:50), mouse-anti-OV6 (1:5000) all
diluted in 1% (v/v) normal goat serum and 0.5% (v/v) BSA in PBS.
The signal was detected using the 3,39 Diaminobenzidine (DAB)
substrate-chromogen kit specific for mouse or rabbit (DAKO
Envision peroxidase system, DAKO) and the sections were
counterstained with hematoxylin before mounting.
Figure 8. Schematic representation of the possible pathways of
differentiation of B13 cells into hepatocytes and ductal cells.
Diagram illustrating the potential relationship between pancreatic
acinar cells, ductal cells and hepatocytes.
doi:10.1371/journal.pone.0013650.g008
Figure 7. CEBPb controls the switch in phenotype from pancreatic B13 cells to hepatocyte or ductal cells. Immunostaining for C/EBPb/
TFN and C/EBPb/PNA in control, Dex and Dex/EGF treated cells (A) and after infection with Ad-CMV-LAP (B) and Ad-CMV-LIP (C). In A only the induced
endogenous C/EBPb is visible. Scale bars, 20m m.
doi:10.1371/journal.pone.0013650.g007
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Protein samples were prepared from cells by freeze-thawing 4
times in a Tris-HCl lysis buffer containing 1:100 dilution of
protease inhibitor cocktail (Sigma, UK). 10 mg of each sample was
run on a 10% Tris-HCl Criterion
TM precast gel and subsequently
transferred to nitrocellulose membrane using the Bio-Rad
Criterion blotter system as described previously [7]. Blots were
probed with the following antibodies diluted in 3% marvel in
PBST (PBS with 0.1% v/v Tween-20, Sigma, UK); mouse-anti-a-
tubulin (1:2000, Sigma,UK), sheep-anti-albumin (1:4000, Biogen-
esis), rabbit-anti-alpha fetoprotein (1:1000, DAKO), rabbit-anti-
TFN (1:2000) and mouse-anti-C/EBPb (1:2000). Secondary
antibodies used were rabbit-anti-sheep Horse radish peroxidase
(HRP) (1:2000, Abcam), goat-anti rabbit HRP (1:2000, Vector)
and horse-anti-mouse HRP (1:2000, Vector).
RT-PCR
Total RNA was isolated using Tri-reagent according to the
manufacturer’s instructions. cDNA synthesis from 2 mg RNA was
carried out using the Superscript
TM First strand Synthesis System
(Invitrogen). PCR was performed using 1 ml of cDNA, Red-
dyMix
TM Master mix (ABgene) and primers for b-actin
(F:TCCGTAAAGACCTCTATGCC, R: AAAGCCATGCCA
AAT GTC TC – 56uC) GSTp (F:TGGAAGGAGGAGGTGGT-
TAC, R: TGTCCCTTCGTCCACTACTG – 54uC) and Cx43
(F:TCTTCATGCTGGTGTC R: TAACCAGCTTGTACC-
CAGG – 60uC). The conditions for amplification were as follows:
initial denaturation at 95uC for 2 min, 25–35 cycles of 94uC for
1 min, 54–60uC for 1 min, 72uC for 1 min, and a final extension
at 72uC for 10 min.
Fluorescence Activated Cell Sorting (FACS) and Magnetic
Activated Cell Sorting (MACS)
The BD FACScanto was used to determine the percentage of
cells with the highest intensity of staining for PNA. Cells were
labelled with FITC-conjugated PNA (1:10) for 15 min prior to
counting in the BD FACScanto. Cells are non-recoverable
following analysis using this protocol, therefore using the
appropriate dilution of PNA:buffer ratio determined by the BD
FACScanto (1:10) the cells were sorted using the MiniMACS
separation system. Briefly, cells were labelled with biotinylated-
PNA (1:10) in MACS buffer (2 mM EDTA, 0.5% BSA in PBS) for
15 min at 4uC, washed in MACS buffer and collected by
centrifugation at 1126g for 4 min. The cell pellet was resuspended
in MACS microbeads conjugated to mouse anti-biotin and
incubated for 15 min at 4uC. The cells were then washed and
resuspended in MACS buffer. The MiniMACS column and
separator were set up according to manufacturers’ instructions and
the microbead/cell mixture added to the column. The negative
fraction was allowed to flow through and collected for further
analysis. The column containing the PNA positive cells was
washed 3 times with MACS buffer. To collect the positive fraction
the column was removed from the magnetic field and 1 ml of
MACS buffer added. The column plunger was used to force the
cells out of the column. Both negative and positive fractions
collected were returned to culture for 2–3 days in the presence of
EGF as described above.
Construction of a CK19-promoter GFP adenovirus
A replication-defective first-generation adenovirus was generat-
ed to express green fluorescent protein (GFP) under the control of
a ductal-specific CK19 promoter [37,38]. To clone the adenoviral
vector, the CMV promoter from pcDNA3 CMV nucGFP plasmid
(GFP under the control of a nuclear localization signal) was
replaced by a 2.1 kb BamHI fragment containing the CK19
promoter elements. A CK19-nucGFP SalI, XbaI fragment of the
resulting construct was then subcloned into a promoterless
pShuttle vector (AdEasy kit, Stratagene) digested with XhoI and
XbaI. The resulting 9.6 kb construct was recombined into a
33.5 kb pAdEasy plasmid (Stratagene) containing the majority of
the adenoviral genome. Recombinants were selected according to
the manufacturer’s instructions. The Ad-CK19-nucGFP adenovi-
rus was transfected and propagated in the human embryonic
kidney (HEK) 293 cell line and purified as previously described
[39]. The virus was titered using the Adeno-X
TM Rapid Titer Kit
(Clontech, CA, USA).
Viral infection of B13 cells
B13 cells were infected with the adenovirus Ad-nucCK19-
nGFP after 6 days of treatment (Dex 4 days then EGF 2 days) at a
multiplicity of infection (MOI) of 200 and incubated overnight in
95% air, 5% CO2 at 37uC. The next day the media was changed
and EGF treatment of the cells continued for a further 3 days.
Following 4 days of Dex treatment B13 cells were also infected
overnight with either the liver activating protein (LAP) or the
liver inhibitory protein (LIP) both at an MOI of 50. Dex
treatment was either continued or switched to EGF for an
additional 6 days. The cells were then PFA fixed and
permeabilised with 0.1% (v/v) Triton X-100 for 30 minutes
before staining.
Electron Microscopy
Control and treated B13 cells were processed for electron
microscopy. Samples were fixed in 2.5% (v/v) glutaraldehyde
(Agar Scientific, Essex, UK) in culture medium without serum for
2 hours. Postfixation took place in a solution of 1% (w/v)
potassium ferrocyanide in 1% (v/v) aqueous osmium tetroxide
(both from Agar Scientific, Essex, UK). Cell pellets were
encapsulated in agarose (Sigma, Poole, UK) and stained in 1%
(w/v) aqueous uranyl acetate (Agar Scientific, Essex, UK). After
dehydration in acetone (Fisher Scientific, Leicestershire, UK)
samples were embedded in epoxy resin (TAAB Laboratories
Equipment, Berks, UK). Sections were viewed in a JEOL 1200Ex
transmission electron microscope (JEOL, Tokyo, Japan) operating
at 80 kv.
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